Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2008

View Archived Issues

Proof-of-concept study supports development of NBI-34041 for anxiety

Postmarketing study finds no increase in nonsuicide death with ziprasidone compared to olanzapine

ASF-1096 investigated in discoid and subacute lupus erythematosus

Aripiprazole data in Asperger's disorder and major depressive disorder reported

Takeda patents use of resatorvid for coronary surgical procedure complications

Pfizer initiates Japanese phase II clinical study of PF-03187207 for glaucoma

NCI files protocol for phase I/II clinical trial of Oncolytics' cancer drug Reolysin

Lundbeck begins phase I clinical studies of Lu-AA-37096 and stops development of Lu-AA-44608

GenVec makes protocol changes to phase II/III PACT trial of TNFerade for pancreatic cancer

ImmunoGen licenses exclusive right to develop IMGN-388 using Centocor antibody

Addex and Merck & Co. to codevelop drug candidate for schizophrenia

FDA approves Shire's new dosages for ADHD treatment Vyvanse

Xanthus' oral fludarabine therapy for CLL receives orphan drug designation

Recent Thallion patent discloses novel antiinfective agents

Recent Bayer patents report novel antithrombotic agents

New phase I/II trial for ispinesib monotherapy in metastatic breast cancer begins

XenoPort begins several clinical trials, gives update on other pipeline products

Amic enters license agreement with Roche Diagnostics for test for cardiac marker NT-proBNP

Takeda submits NDA for alogliptin in the U.S.

Addex announces ADX-10059 phase IIa acute anxiety data

Anti-HIV drug apricitabine enters phase III

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...